middle.news
Vectus clears FDA pre-IND step for VB0004 fibrosis drug
5:01pm on Thursday 29th of October, 2026 AEDT
•
Biotechnology
Read Story
Vectus clears FDA pre-IND step for VB0004 fibrosis drug
5:01pm on Thursday 29th of October, 2026 AEDT
Key Points
FDA written responses on VB0004 expected by mid-November 2026
Cardinal Health Regulatory Services appointed as US regulatory agent
Phase Ia study completed with favourable safety and pharmacokinetic profile
$309,000 used in operating activities during the September quarter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE